{"id":"W2404824632","doi":"10.1182/blood.v124.21.4457.4457","title":"Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; McGill University; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Cohort; Rituximab; Refractory (planetary science); Gastroenterology; Follicular lymphoma; Lymphoma; Oncology; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00354735,0.0008842048,0.001712249,0.0003346571,0.0002452752,0.001057317,0.0007668508,0.0008287533,0.001941704],"category_scores_gemma":[0.002441825,0.0004362899,0.001525462,0.0003659877,0.0006036544,0.0007424045,0.0004490761,0.001435764,0.0003328301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007976997,"about_ca_system_score_gemma":0.0007917552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006617671,"about_ca_topic_score_gemma":0.001535697,"domain_scores_codex":[0.9981832,0.001239727,0.0001356947,0.0001809483,0.0001218623,0.0001385673],"domain_scores_gemma":[0.998192,0.0006027013,0.0005007312,0.0001684957,0.0001144478,0.0004216426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9144908,0.007430255,0.009155945,0.0004955977,0.003924731,0.0001217343,0.0001289456,0.0007170499,0.01203793,0.00008387877,0.001560172,0.04985303],"study_design_scores_gemma":[0.7751034,0.1832281,0.03155504,0.00004549355,0.004039434,0.0002169844,0.00004781475,0.0006967895,0.002417045,0.0001213464,0.002495243,0.00003328722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937903,0.002464713,0.0003557433,0.000273651,0.0001205908,0.001000822,0.0009180202,0.00004529555,0.001030765],"genre_scores_gemma":[0.9937861,0.0008717982,0.0009121597,0.0006301836,0.0002529757,0.0007670694,0.00203544,0.00001802429,0.0007263412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00354735,"threshold_uncertainty_score":0.01876044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007494244142693291,"score_gpt":0.2521085767412386,"score_spread":0.2446143325985453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}